Immatics/$IMTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Immatics

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Ticker

$IMTX
Sector
Primary listing

Employees

618

Immatics Metrics

BasicAdvanced
$1.1B
-
-$0.76
1.02
-

What the Analysts think about Immatics

Analyst ratings (Buy, Hold, Sell) for Immatics stock.

Bulls say / Bears say

Immatics reported positive Phase 1b ASCO data for anzu-cel, showing a 56% confirmed overall response rate and a median response duration of 12.1 months in heavily pretreated metastatic melanoma patients.
The company closed Q2 2025 with $560.5 million in cash and equivalents, securing funding through the second half of 2027 to support ongoing R&D activities.
Immatics received a milestone payment under its 2023 collaboration with Moderna after Moderna began its first Phase 1 clinical trial, validating Immatics’ XPRESIDENT® target discovery platform.
Revenue from collaboration agreements plunged to $5.5 million in Q2 2025 from $22.0 million a year earlier, highlighting volatility in partnership income and weakening near-term cash flow.
Net loss widened to $82.4 million for Q2 2025 compared to a loss of $21.1 million in Q2 2024, reflecting strong cash outflows from higher R&D costs and foreign exchange losses.
IMTX reported a Q2 2025 loss of $0.66 per share, missing the Zacks Consensus Estimate of a $0.38 loss, and missed revenue by more than 62%, pointing to continued earnings pressure.
Data summarised monthly by Lightyear AI. Last updated on 1 Oct 2025.

Immatics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immatics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs